Immunitas Therapeutics
The Human Approach to Oncology
33 employees · est. 2019 · Waltham, United States
Merus N.V.
Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c
253 employees · est. 2003 · Utrecht, The Netherlands
Merus N.V. is the older company (2019 vs 2003); Merus N.V. is the larger of the two.
Side-by-Side Comparison
| Metric | Immunitas Therapeutics | Merus N.V. |
|---|---|---|
| Founded | ||
| Founded | 2019 | 2003 older |
| Headquarters | ||
| Headquarters | Waltham, United States | Utrecht, The Netherlands |
| Employees | ||
| Employees | 33 | 253 larger |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Series B | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $97.00M | $1.04B |
| Funding Rounds | ||
| Funding Rounds | 2 | 11 |
| Services | ||
| Services | Development of novel therapeutics, Preclinical and clinical research, Drug licensing and partnerships | Development of Cancer Treatments, Clinical Trials Management, Research and Development in Biotechnology, Multiclonics Therapeutics |
| Target Customers | ||
| Target Customers | Cancer patients, Patients with autoimmune diseases, Pharmaceutical companies | Cancer Patients, Healthcare Providers, Medical Researchers, Pharmaceutical Industry |
| Taxonomy | ||
| Taxonomy | Immuno-oncology, Therapeutics, Single Cell Genomics, T & NK Cell Modulator, Antibody Discovery, Human Immunology, Novel Drug Targets, Biomarker Development, Antibody Engineering, Clinical Research, Oncology, Investment, Medical Research | Biclonics®, Bispecific Antibody Therapeutics, Antibody-based Biopharmaceuticals, Oligoclonics Technology, Immuno-oncology, Cancer Treatment, Antibody Engineering, Tumor Cell Inhibition, Immune System Activation, Biomarker Development, Clinical Trials, Oncology Research, Therapeutic Antibodies, Antibody Discovery, Cell Biology |
| Website | ||
| Website | immunitastx.com | merus.nl |
About Immunitas Therapeutics
Immunitas Therapeutics, with its slogan "The Human Approach to Oncology", is revolutionizing the field of immuno-oncology therapeutics. Founded in 2019, the company leverages a unique cross-functional, single cell genomics platform to efficiently identify and validate targets while simultaneously di...
About Merus N.V.
Merus N.V., a biotechnology firm founded in 2003, is headquartered in The Netherlands. The company is at the forefront of developing innovative oncology solutions using its proprietary Biclonics® bispecific antibody therapeutics. This pioneering approach enables simultaneous multi-targeted tumor att...
We will tell you when either one moves
BounceWatch watches Immunitas Therapeutics and Merus N.V. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Immunitas Therapeutics and Merus N.V. — by email.
Frequently Asked Questions
Compare Immunitas Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Immunitas Therapeutics on 11 Sep 2024, and Merus N.V. on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
